Outcomes of Bimagrumab in sIBM, Sarcopenia, and Obesity Trials Bimagrumab consistently increased lean mass by 3.67% across trials in sIBM, sarcopenia, posthip fracture recovery, and obesity, with reductions in fat mass of 1021% in sarcopenia and obesity
Subsequently, Glyoxalase II converts S-D-Lactoyl-glutathione to Reduced Glutathione and D-lactate
[1] [2] These medicines include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro), which is a dual GIP/GLP-1 receptor agonist
If you have any questions or need personalized assistance, dont hesitate to reach out to us at Vive Ageless Weight Loss Centerwere here to support you every step of the way